TY  - JOUR
T1  - Cannabinoids Involvement in Neurodegenerative Diseases
AU - Milano, Walter AU - Capasso, Anna 
JO  - Research Journal of Pharmacology
VL  - 13
IS  - 2
SP  - 16
EP  - 26
PY  - 2019
DA  - 2001/08/19
SN  - 1815-9362
DO  - rjpharm.2019.16.26
UR  - https://makhillpublications.co/view-article.php?doi=rjpharm.2019.16.26
KW  - Cannabinoids
KW  -mental and motor dysfuction
KW  -neuroprotection
KW  -system
KW  -element
KW  -activity
AB  - The cannabinoids are found to have particular application as neuroprotectants for mental and motor
dysfuction in neurodegenerative diseases. The neuroprotective properties of cannabinoids suggest their
therapeutic use for limiting neurological damage. The cannabinoids treatments should not only aim to alleviate
specific symptoms but also, attempt to delay/arrest disease progression and to repair the damaged structures.
The researcher conducted a review of studies published between 1974 and 2011. The search was performed
using the following PubMed search terms: "Cannabinoids" and "Neurodegenerative Diseases" and 287 papers
were detected. The study were examined and the overlapping or insufficiently clear works were excluded.
Finally, we chose 117 articles regarding the latest international guidelines, the pathophysiology of
neurodegenerative diseases and the various therapeutic choices. The studies reported in the present review
support the view that the cannabinoid signalling system is a key modulatory element in the activity of the basal
ganglia. This idea is supported by different anatomical, electrophysiological, pharmacological and biochemical
data. Furthermore, these studies indicate that the cannabinoid system is impaired in different neurological
disorders that directly or indirectly affect the basal ganglia which supports the idea of developing novel
pharmacotherapies with compounds that selectively target specific elements of the cannabinoid system.
ER  -